32919-24-7

Upstream product

• 586-95-8 pyridine-4-methanol 
• 5070-13-3 bis-(p-nitrophenyl) carbonate 
• 7693-46-1 4-Nitrophenyl chloroformate 

Downstream Products

• 1198765-72-8 pyridin-4-ylmethyl [(1R)-2-hydroxy-1-phenylethyl] carbamate 
• 1535202-81-3 methyl (1R,15S,17R,18R,19S,20S)-17-[(3,5-dimethoxy-4 {[(pyridin-4-ylmethoxy)carbonyl]oxy}phenyl)carbonyloxy]-6,18-dimethoxy-3,13-diazapentacyclo[11.8.0.0^2,10.0^4,9.0^15,20]henicosa-2⁽¹⁰⁾,4,6,8-tetraene-19-carboxylate 

Relevant academic research and scientific papers

COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION

The invention relates to novel Rauwolfia alkaloid derivatives of formula (I) combinations of Rauwolfia alkaloid derivatives and a mitochondrial inhibitor, e.g. metformin, and the use of Rauwolfia alkaloid derivatives in combination with mitochondrial inhibitor for the treatment of cancer and for achieving clinical immunosuppression. The invention also relates to a fluorescence-based method for predicting the sensitivity of a cancer cell towards a compound of formula (I).

Chemoenzymatic synthesis of the immunoglobulin domain of tim-3 carrying a complex-type N-glycan by using a one-pot ligation

Ligations: The title immunoglobin (Ig) domain was chemoenzymatically synthesized. The domain was divided into three segments and N- and S-protected peptide thioesters were synthesized by solid-phase peptide synthesis. The one-pot sequential ligation was achieved by using Ag+-free and Ag+-assisted activation of the thioester. After folding and enzymatic transfer of the synthetic glycan, the desired Ig domain carrying a nonasaccharide was successfully obtained. Copyright

Proteasome inhibition by peptide-semicarbazones

Peptide-semicarbazones derived from Z-Trp-Trp-Phe-aldehyde inhibit the chymotryptic activity of the human proteasome at nanomolar concentrations, but are less active in a NFκB reporter gene assay. Cyclic semicarbazones, in contrast, combine a strong inhib

USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS

The present invention relates to the new use of 2,4-diamino-3-hydroxycarboxylic acids of formula (I), in which A and B independently represent a bond or an unsubstituted or substituted amino acyl moiety; R1 represents hydrogen; an amino protecting group;

Dipeptide derivatives having an enzyme inhibitory action

Dipeptide derivatives having an enzyme inhibitory action Compounds of the formula I STR1 in which R1 represents a (substituted) heterocyclyl-alkyl, -alkoxy, -cycloalkyl or -cycloalkoxy and the corresponding heterocyclylmercapto radicals, A and B independently of one another denote an amino acid, R2 is hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, aryl or aryl-alkyl, R3 represents hydrogen, alkyl, aryl, aryl-alkyl or hydroxyl and R4 denotes a radical (CH2)0-4 CHR5 -D where R5 =hydrogen, alkyl, alkoxy, alkylthio, alkylamino, hydroxyl, azido or halogen and D=(substituted) heterocyclyl, have enzyme-inhibiting properties. Processes for the preparation of compounds of the formula I and their use in the treatment of hypertension and viral diseases are described.